Star Equity Holdings, Inc. Announces 2020 Fourth Quarter and Year End Financial Results (unaudited)

March 9, 2021 6:00 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

OLD GREENWICH, CT, March 09, 2021 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star” or the “Company”) reported today its financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2020. All 2020 and 2019 amounts in this release are unaudited.

On January 1, 2021, Digirad Corporation was renamed Star Equity Holdings, Inc. Concurrent with our name change, the Company changed its common stock ticker from DRAD to STRR. Since the acquisition of ATRM Holdings, Inc. on September 10, 2019, Star has transformed into a diversified, multi-industry holding company with three business divisions: Digirad Health, Star Building & Construction, and Star Real Estate & Investments.

Financial results for both the 2020 and 2019 reporting periods include financial and operational data (starting September 10, 2019) of the two newly created divisions, Star Building & Construction and Star Real Estate & Investments. Furthermore, during the fourth quarter of 2020, Star entered into a Stock Purchase Agreement to sell DMS Health Technologies, Inc., a portion of our healthcare business which operates the Company’s Mobile Healthcare segment, for $18.75 million. Related financial and operational data for the Mobile Healthcare business was classified as discontinued operations for all reporting periods ending of December 31, 2020 and 2019. The results presented below relate to continuing operations, which encompass Digirad Health (Diagnostic Services and Diagnostic Imaging), Star Building & Construction, and Star Real Estate & Investments and discontinued operations, which consist of Mobile Healthcare. Mobile Healthcare’s assets and liabilities are reported as “Assets held for sale” and “Liabilities held for sale” on the balance sheet as of December 31, 2020 and 2019.

The COVID-19 pandemic had a significant impact on our 2020 financial results. Our businesses began to recover in the second half of 2020 and we are hopeful this recovery will continue as the vaccine rollout progresses. We are proud of our front line employees who continue to provide healthcare services in the face of the increased risk presented by the pandemic.

Q4 2020 Financial Highlights vs. Q4 2019 (unaudited)

  • Total revenue from continuing operations decreased by 9.5% to $23.1 million from $25.6 million; total revenue from discontinued operations decreased by 10.4% to $9.5 million from $10.6 million
  • Gross profit from continuing operations decreased by 38.5% to $3.9 million from $6.3 million; gross profit from discontinued operations decreased by 18.1% to $1.3 million from $1.6 million
  • Net loss from continuing operations was $0.5 million (or $0.10 per basic and diluted share), as compared to a net loss from continuing operations of $0.3 million (or $0.14 per basic and diluted share); net income from discontinued operations was $41.0 thousand, as compared to a net income from discontinued operations of $35.0 thousand*
  • Non-GAAP adjusted EBITDA from continuing operations decreased by 159.1% to negative $0.7 million from $1.2 million; non-GAAP adjusted EBITDA from discontinued operations decreased by 8.2% to $1.8 million from $2.0 million
  • Non-GAAP consolidated free cash outflow of $1.4 million versus inflow of $1.4 million

FY 2020 Financial Highlights vs. FY 2019 (unaudited)

  • Total revenue from continuing operations increased by 7.2% to $78.2 million from $72.9 million; total revenue from discontinued operations decreased by 12.7% to $36.0 million from $41.3 million
  • Gross profit from continuing operations decreased by 18.5% to $14.0 million from $17.2 million; gross profit from discontinued operations decreased by 8.8% to $4.5 million from $5.0 million
  • Net loss from continuing operations was $5.3 million (or $1.44 per basic and diluted share), as compared to a net loss from continuing operations of $2.7 million (or $1.34 per basic and diluted share); net loss from discontinued operations was $1.2 million, as compared to $1.9 million*
  • Cash and cash equivalents and restricted cash for continuing operations of $3.4 million versus $2.0 million; net debt remained approximately $21.0 million
  • Non-GAAP adjusted EBITDA from continuing operations decreased by 117.7% to negative $0.6 million from $3.6 million; non-GAAP adjusted EBITDA from discontinued operations remained flat versus the prior year at $6.2 million
  • Non-GAAP consolidated free cash outflow of $3.7 million versus inflow of $3.0 million

* On May 28, 2020, Star completed a public offering through the issuance of 2,225,000 shares of its common stock. Per share amounts for Q4 2020 and FY 2020 periods, reflect the new share count. For FY 2020, there were 0.49 million warrants exercised and converted into 0.24 million shares of common stock.

Jeff Eberwein, Executive Chairman of Star, noted, “FY 2020 was a challenging, but exciting, year for Star. While our business experienced reduced revenue due to the COVID-19 pandemic, we made significant progress on our growth and value maximization strategy by improving operating and financial results at our Building & Construction division and by announcing the sale of certain assets in our Digirad Health division for over $20 million. The MD Office Solutions transaction closed on February 1, 2021 and the sale of Mobile Healthcare is expected to close in Q1 2021. Also, we rebranded the public company to better reflect our business strategy and structure.”

Mr. Eberwein continued, “In Q4 2020, our Digirad Health division continued to be impacted by lower sales of new cameras and reduced camera services due to the pandemic. Heading into 2021, however, our backlog of service contracts has improved and is expected to return to normal levels as the year progresses. In 2020, sales of new cameras declined 59% versus 2019, and is expected to improve somewhat in 2021, but remains dependent upon capital spending decisions by healthcare providers. At our Building & Construction division, Q4 2020 revenue improved by 15% versus Q4 2019 and 15% versus Q3 2020. Gross margins in Q4 2020 were adversely impacted by an extreme rise in raw materials prices. We increased prices in January to offset these higher input costs, and our backlog remains very strong. We continue to expect margins in Building & Construction to improve over time and we have made progress on our goal of substantially increasing our output capacity at our KBS business. Our plan is to increase our production to 15 - 20 modules per week versus the current run rate of approximately 7.5 per week and we expect to make progress on this goal in 2021.

With an estimated $18 million in immediate cash proceeds from the aforementioned sale that is expected to close in Q1 2021, we expect to pay down some of our higher-cost debt and fund high-return internal growth investments. We will also continue to explore acquisitions, which could be either bolt-ons for our existing businesses or new platform companies, which would create new business segments to our holding company structure.”

Revenues

Revenues in thousands (Unaudited) Q4 2020 Q4 2019 % change FY 2020 FY 2019 % change
Digirad Health $13,324  $16,958  (21.4)% $49,232  $61,595  (20.1)%
Star Building & Construction 9,818  8,528  15.1 % 28,879  11,257  156.5 %
Star Real Estate & Investments 160  232  (31.0)% 685  275  149.1 %
Corporate, eliminations and other (158) (158)  % (633) (193) 228.0 %
Total Revenues from continuing operations $23,144  $25,560  (9.5)% $78,163  $72,934  7.2 %
                         

Digirad Health revenue for Q4 2020 and FY 2020 decreased due to the slowdown related to the COVID-19 pandemic. Although many doctor offices have re-opened and hospitals have started to once again perform non-emergency procedures, activity remains below pre-COVID-19 levels.

Star Building & Construction revenue for Q4 2020 and FY 2020 increased by 15.1% and 156.5%, respectively, mainly due to two significant commercial construction projects at our subsidiary KBS Builders, Inc. (“KBS”) in 2020.

The revenue decrease from discontinued operations for both reporting periods is attributable to the effects of COVID-19.

Gross Profit

Gross profit in thousands (Unaudited) Q4 2020 Q4 2019 % change FY 2020 FY 2019 % change
Digirad Health $2,615  $4,786  (45.4)% $10,149  $15,373  (34.0)%
Star Building & Construction 1,339  1,536  (12.8)% 4,047  2,013  101.0 %
Star Real Estate & Investments 95  167  (43.1)% 424  (33) (1,384.8)%
Corporate, eliminations and other (158) (158)  % (633) (193) 228.0 %
Total Gross profit from continuing operations $3,891  $6,331  (38.5)% $13,987  $17,160  (18.5)%
                         

Gross profit for the Digirad Health division for Q4 2020 and FY 2020 decreased compared to the same periods of 2019 due to lower revenue from mobile scanning services and lower sales of new cameras, primarily as a result of the COVID-19 pandemic.

Gross profit of our Star Building & Construction division for FY 2020 doubled compared to FY 2019, as FY 2020 includes a full year of operational data from this division compared to a portion of the year in 2019. Gross profit of our Star Building & Construction division for Q4 2020 decreased by 12.8%, from prior year same period, due to the negative effect of higher raw material prices.

Gross profit from discontinued operations for both reporting periods decreased due to lower revenues.

Operating Expenses

Q4 2020 selling, general and administrative (SG&A) expenses decreased by 0.6% or $32.0 thousand from the same period of 2019, mainly due to lower headcount, lower healthcare expenses, and reduced costs for contracted services, particularly in the information technology (IT) and human resources (HR) areas from our Digirad Health division. Our FY 2020 SG&A expenses increased by 17.2% or $2.7 million, compared to FY 2019, due to $3.0 million in higher expenses from our Star Building & Construction division such as amortization of intangible assets of $2.0 million in 2020 compared to $0.7 million in 2019 (FY 2020 includes a full year of SG&A expenses for this division), partially offset by lower salaries and benefits resulting from lower headcount and reduced costs for contracted services particularly in IT and HR areas as a result of steps we took to streamline our internal operations. Additionally, we incurred $0.4 million goodwill non-cash impairment charges in Q4 2020 compared to prior year, primarily as a result of impairment recorded in our EBGL reporting unit.

Operating expenses from discontinued operations were $1.2 million and $1.8 million in Q4 2020 and Q4 2019, respectively, and $5.4 million and $6.9 million in FY2020 and FY2019, respectively.

Net loss

Q4 2020 net loss from continuing operations was $0.5 million, or $0.10 loss per basic and diluted share, compared to a net loss from continuing operations of $0.3 million, or $0.14 loss per basic and diluted share in the same period of the prior year. Q4 2020 non-GAAP adjusted net loss from continuing operations was $1.6 million, or $0.34 loss per basic and diluted share, compared to an adjusted non-GAAP net income of $0.4 million, or $0.22 income per basic and diluted share in the same period of the prior year.

FY 2020 net loss from continuing operations was $5.3 million, or $1.44 loss per basic and diluted share, compared to a net loss from continuing operations of $2.7 million, or $1.34 loss per basic and diluted share in FY 2019. FY 2020 non-GAAP adjusted net loss from continuing operations was $4.3 million, or $1.17 loss per basic and diluted share, compared to an adjusted non-GAAP net income of $0.7 million, or $0.36 income per basic and diluted share in the prior year.

Q4 2020 net income from discontinued operations was $41.0 thousand compared to a net income from discontinued operations of $35.0 thousand in the same period of the prior year. FY 2020 net loss from discontinued operations was $1.2 million, compared to a net loss from discontinued operations of $1.9 million in FY 2019.

Non-GAAP adjusted EBITDA

Q4 2020 non-GAAP adjusted EBITDA from continuing operations decreased to negative $0.7 million from positive $1.2 million in the same quarter of the prior year due to lower revenue generated from high-margin mobile scanning services because of the COVID-19 pandemic. FY 2020 non-GAAP adjusted EBITDA from continuing operations decreased to negative $0.6 million, compared to positive $3.6 million in FY 2019, reflecting COVID-19 impact.

Q4 2020 non-GAAP adjusted EBITDA from discontinued operations decreased to $1.8 million from $2.0 million in the same quarter of the prior year. FY 2020 non-GAAP adjusted EBITDA from discontinued operations remained flat versus the prior year at $6.2 million.

Operating cash flow

Q4 2020 cash flow from consolidated operations (including continuing and discontinued operations) was an outflow of $3.1 million, compared to an inflow of $1.2 million for the same period in the prior year. FY 2020 cash flow from operations was an outflow of $5.0 million, compared to an inflow of $0.4 million for FY 2019, primarily as a result of the impact of COVID-19, as well as changes in working capital.

Non-GAAP free cash flow

The Company calculates a non-GAAP measure of consolidated free cash flow. The Company defines free cash flow as net cash provided by (used in) operating activities for continuing and discontinued operations, less purchases of property and equipment, plus net dispositions and estimated level of one-time acquisition related net working capital adjustments at the closing date. The Company believes that this measure of free cash flow provides management and investors further useful information on cash generation or use in our primary operations. The most directly comparable measure for the liquidity measure is cash flow from operating activities.

Q4 2020 non-GAAP free cash flow was an outflow of $1.4 million, compared to an inflow of $1.4 million of the same quarter in the prior year. FY 2020 non-GAAP free cash flow was an outflow of $3.7 million, compared to an inflow of $3.0 million in FY 2019, primarily as a result of the impact of COVID-19.

Net operating loss (NOL)

Star has approximately $94.9 million of federal net operating losses (“NOL”) in the U.S. as of year-end 2020, which the Company considers to be a very valuable asset for its stockholders. In order to protect the value of the NOL for all stockholders, the Company has a charter amendment in place that limits beneficial ownership of Star common stock to 4.99%. Stockholders who wish to own more than 4.99% of Star common stock, or who already own more than 4.99% of Star common stock and wish to buy more, may only acquire additional shares with the Board’s prior written approval.

Conference Call Information

A conference call is scheduled for 10:00 a.m. ET (7:00 a.m. PT) on March 9, 2021 to discuss the results and management’s outlook. The call may be accessed by dialing 1-877-407-9039 (international callers: +1-201-689-8470) five minutes prior to the scheduled start time and referencing Star. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at starequity.com/events-and-presentations/presentations; an archived replay of the webcast will be available within 15 minutes of the end of the conference call.

If you have any questions, either prior to or after our scheduled Earnings Conference call, please e-mail admin@starequity.com or lcati@equityny.com.

Use of Non-GAAP Financial and Liquidity Measures by Star Equity Holdings, Inc.

This release presents the non-GAAP financial measures “adjusted net income (loss),” “adjusted net income (loss) per basic and diluted share,” “free cash flow”, and “adjusted EBITDA.” The most directly comparable measure for these non-GAAP financial measures are net income and basic and diluted net income per share. The Company has included below adjusted financial information, which presents the Company’s results of operations after excluding acquired intangible asset amortization, acquisition related contingent consideration adjustments, unrealized gain (loss) on available-for-sale securities, and non-recurring related income tax adjustments. Further excluded in the measure of adjusted EBITDA are interest, taxes, depreciation, amortization, and stock-based compensation.

A discussion of the reasons why management believes that the presentation of non-GAAP financial and liquidity measures provides useful information to investors regarding the Company’s financial condition, results of operations and cash flows is included as Exhibit 99.2 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on March 9, 2021.

About Star Equity Holdings, Inc.

Star Equity Holdings, Inc. is a diversified holding entity with three divisions: Digirad Health, Star Building & Construction, and Star Real Estate & Investments.

Digirad Health

Digirad Health designs, manufactures, and distributes diagnostic medical imaging products and provides mobile imaging services. Digirad Health operates in two businesses: (i) diagnostic services and (ii) diagnostic imaging. The diagnostic services business offers imaging services to healthcare providers as an outsourced alternative to purchasing and operating their own equipment. The diagnostic imaging business develops, sells, and maintains solid-state gamma cameras.

Star Building & Construction

Star Building & Construction manufactures modular housing units for commercial and residential real estate projects and operates in two businesses: (i) modular building manufacturing and (ii) structural wall panel and wood foundation manufacturing, including building supply retail operations.

Star Real Estate & Investments

Star Real Estate & Investments manages and finances real estate assets and investments.

Forward-Looking Statements

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this release that are not statements of historical fact are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking Statements include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to acquisitions and related integration, development of commercially viable products, novel technologies, and modern applicable services, (ii) projections of income (including income/loss), EBITDA, earnings (including earnings/loss) per share, free cash flow (FCF), capital expenditures, cost reductions, capital structure or other financial items, (iii) the future financial performance of the Company or acquisition targets and (iv) the assumptions underlying or relating to any statement described above. Moreover, forward-looking statements necessarily involve assumptions on the Company’s part. These forward-looking statements generally are identified by the words “believe”, “expect”, “anticipate”, “estimate”, “project”, “intend”, “plan”, “should”, “may”, “will”, “would”, “will be”, “will continue” or similar expressions. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described above as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the substantial amount of debt of the Company and the Company’s ability to repay or refinance it or incur additional debt in the future; the Company’s need for a significant amount of cash to service and repay the debt and to pay dividends on the Company’s preferred stock; the restrictions contained in the debt agreements that limit the discretion of management in operating the business; legal, regulatory, political and economic risks in markets and public health crises that reduce economic activity and cause restrictions on operations (including the recent coronavirus COVID-19 outbreak); the length of time associated with servicing customers; losses of significant contracts or failure to get potential contracts being discussed; disruptions in the relationship with third party vendors; accounts receivable turnover; insufficient cash flows and resulting lack of liquidity; the Company's inability to expand the Company's business; unfavorable changes in the extensive governmental legislation and regulations governing healthcare providers and the provision of healthcare services and the competitive impact of such changes (including unfavorable changes to reimbursement policies); high costs of regulatory compliance; the liability and compliance costs regarding environmental regulations; the underlying condition of the technology support industry; the lack of product diversification; development and introduction of new technologies and intense competition in the healthcare industry; existing or increased competition; risks to the price and volatility of the Company’s common stock and preferred stock; stock volatility and in liquidity; risks to preferred stockholders of not receiving dividends and risks to the Company’s ability to pursue growth opportunities if the Company continues to pay dividends according to the terms of the Company’s preferred stock; the Company’s ability to execute on its business strategy (including any cost reduction plans); the Company’s failure to realize expected benefits of restructuring and cost-cutting actions; the Company’s ability to preserve and monetize its net operating losses; risks associated with the Company’s possible pursuit of acquisitions; the Company’s ability to consummate successful acquisitions and execute related integration, as well as factors related to the Company’s business including economic and financial market conditions generally and economic conditions in the Company’s markets; failure to keep pace with evolving technologies and difficulties integrating technologies; system failures; losses of key management personnel and the inability to attract and retain highly qualified management and personnel in the future; and the continued demand for and market acceptance of the Company’s services. For a detailed discussion of cautionary statements and risks that may affect the Company’s future results of operations and financial results, please refer to the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the risk factors in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. This release reflects management’s views as of the date presented.

All forward-looking statements are necessarily only estimates of future results, and there can be no assurance that actual results will not differ materially from expectations, and, therefore, you are cautioned not to place undue reliance on such statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.

For more information contact:  
Star Equity Holdings, Inc.The Equity Group 
Jeffrey E. EberweinLena Cati 
Executive ChairmanVice President 
203-489-9501212-836-9611 
admin@starequity.comlcati@equityny.com 
   

(Financial tables follow)

Star Equity Holdings, Inc.Condensed Consolidated Statements of Operations(Unaudited)(In thousands, except for per share amounts)

  Three Months Ended December 31, Twelve Months Ended December 31,
  2020 2019 2020 2019
Revenues:        
Digirad Health $13,324   $16,958   $49,232   $61,595  
Star Building & Construction 9,818   8,528   28,879   11,257  
Star Real Estate & Investments 2   74   52   82  
Total revenues 23,144   25,560   78,163   72,934  
Cost of revenues:        
Digirad Health 10,709   12,172   39,083   46,222  
Star Building & Construction 8,479   6,992   24,832   9,244  
Star Real Estate & Investments 65   65   261   308  
Total cost of revenues 19,253   19,229   64,176   55,774  
Gross profit 3,891   6,331   13,987   17,160  
Total gross profit percentage 16.8 % 24.8 % 17.9 % 23.5 %
Digirad Health  19.6 % 28.2 % 20.6 % 25.0 %
Star Building & Construction 13.6 % 18.0 % 14.0 % 17.9 %
Star Real Estate & Investments N/M* N/M N/M N/M
Operating expenses:        
Selling, general and administrative 5,574   5,606   18,635   15,898  
Amortization of intangible assets 428   588   2,124   829  
Merger and financing costs    284      2,342  
Goodwill impairment 436      436     
Total operating expenses 6,438   6,478   21,195   19,069  
Loss from continuing operations (2,547)  (147)  (7,208)  (1,909) 
Other income (expense):        
Other income (expense), net 2,377   67   3,344   (133) 
Interest expense, net (284)  (313)  (1,292)  (746) 
Loss on extinguishment of debt          (151) 
Total other income (expense) 2,093   (246)  2,052   (1,030) 
Loss from continuing operations before income taxes (454)  (393)  (5,156)  (2,939) 
Income tax (expense) benefit (43)  102   (129)  199  
Loss from continuing operations, net of income taxes (497)  (291)  (5,285)  (2,740) 
Income (loss) from discontinued operations, net of income taxes 41   35   (1,172)  (1,887) 
Net loss (456)  (256)  (6,457)  (4,627) 
Deemed dividend on Series A cumulative perpetual preferred stock (474)  (490)  (1,916)  (596) 
Net loss attributable to common shareholders $(930)  $(746)  $(8,373)  $(5,223) 
         
Net loss per common share - basic and diluted        
Net loss per share, continuing operations $(0.10)  $(0.14)  $(1.44)  $(1.34) 
Net income (loss) per share, discontinued operations 0.01   0.02   (0.32)  (0.93) 
Net loss per share (0.09)  (0.12)  (1.76)  (2.27) 
Deemed dividend on Series A cumulative perpetual preferred stock per share (0.10)  (0.24)  (0.52)  (0.29) 
Net loss per share, attributable to common shareholders - basic and diluted $(0.19)  $(0.36)  $(2.28)  $(2.56) 
Weighted-average shares outstanding – basic and diluted 4,785   2,050   3,659   2,041  
         
Net loss $(456)  $(256)  $(6,457)  $(4,627) 
Other comprehensive loss:        
Reclassification of tax provision impact          22  
Total other comprehensive income          22  
Comprehensive loss $(456)  $(256)  $(6,457)  $(4,605) 
                     

N/M* - Not meaningful, as this is an internal division with de minimis external revenue.

Star Equity Holdings, Inc.Condensed Consolidated Balance Sheets (Unaudited)(In thousands)

  December 31,2020 December 31,2019
Assets:    
Current assets:    
Cash and cash equivalents $3,225  $1,747 
Restricted cash 168  240 
Equity securities 35  26 
Accounts receivable, net 12,975  12,916 
Inventories, net 9,787  7,029 
Other current assets 1,990  1,339 
Assets held for sale 20,756  24,573 
Total current assets 48,936  47,870 
Property and equipment, net 9,762  10,286 
Operating lease right-of-use assets 1,769  2,238 
Intangible assets, net 16,900  19,023 
Goodwill 9,542  9,978 
Other assets 1,384  1,165 
Total assets $88,293  $90,560 
     
Liabilities, Mezzanine Equity and Stockholders’ Equity:    
Current liabilities:    
Accounts payable $4,952  $6,462 
Accrued compensation 2,825  3,747 
Accrued warranty 214  421 
Deferred revenue 2,184  1,776 
Short-term debt 5,652  4,036 
Notes payable to related parties 2,307  1,919 
Operating lease liabilities 1,011  1,144 
Other current liabilities 3,000  4,186 
Liabilities held-for-sale 7,871  6,985 
Total current liabilities 30,016  30,676 
Long-term debt, net of current portion 16,410  17,038 
Deferred tax liabilities 51  11 
Operating lease liabilities, net of current portion 828  1,206 
Other liabilities 1,059  932 
Total liabilities 48,364  49,863 
     
Preferred stock, $0.0001 par value: 10,000,000 shares authorized: 10% Series A Cumulative Perpetual Preferred Stock 8,000,000 shares authorized, liquidation preference ($10.00 per share), 1,915,637 shares issued and outstanding at December 31, 2020 and 2019, respectively 21,500  19,602 
     
Stockholders’ equity:    
Common stock, $0.0001 par value: 30,000,000 shares authorized; 4,798,367 and 2,050,659 shares issued and outstanding (net of treasury shares) at December 31, 2020 and 2019, respectively    
Treasury stock, at cost; 258,849 shares at December 31, 2020 and December 31, 2019 (5,728) (5,728)
Additional paid-in capital 149,143  145,352 
Accumulated deficit (124,986) (118,529)
Total stockholders’ equity 18,429  21,095 
Total liabilities, mezzanine equity and stockholders’ equity $88,293  $90,560 
         

Star Equity Holdings, Inc.Reconciliation of Non-GAAP Financial Measures(Unaudited)(In thousands)

  Three Months Ended December 31, Twelve Months Ended December 31,
  2020 2019 2020 2019
         
Net loss from continuing operations $(497) $(291) $(5,285) $(2,740)
Acquired intangible amortization 428  588  2,124  829 
Unrealized loss (gain) on equity securities (1) 11  (33) (22) (62)
Litigation costs (2) 318    562   
Loss on extinguishment of debt       151 
Goodwill impairment (3) 436    436   
Write-off of Star Real Estate Holding assets       143 
Transaction cost (4)   284  115  2,342 
Write-off of preferred stock issuance cost (5)       273 
Financing costs 78    78   
Personal protection equipment (6) 17    63   
SBA PPP Loan forgiveness (2,470)   (2,470)  
Income tax expense (benefit) 43  (102) 129  (199)
Non-GAAP adjusted net (loss) income from continuing operations $(1,636) $446  $(4,270) $737 
         
Net loss per diluted share from continuing operations $(0.10) $(0.14) $(1.44) $(1.34)
Acquired intangible amortization 0.09  0.29  0.58  0.41 
Unrealized loss (gain) on equity securities (1)   (0.02) (0.01) (0.03)
Litigation costs (2) 0.07    0.15   
Loss on extinguishment of debt       0.07 
Goodwill impairment (3) 0.09    0.12   
Write-off of Star Real Estate Holding assets       0.07 
Transaction cost (4)   0.14  0.03  1.15 
Write-off of preferred stock issuance cost (5)       0.13 
Financing costs 0.02    0.02   
Personal protection equipment (6)     0.02   
SBA PPP Loan forgiveness (0.52)   (0.68)  
Income tax expense (benefit) 0.01  (0.05) 0.04  (0.10)
Non-GAAP adjusted net (loss) income per basic and diluted share from continuing operations (7) $(0.34) $0.22  $(1.17) $0.36 
                 

(1)   Reflects change in fair value of investments in equity securities.(2)   Reflects one-time litigation costs.(3)   Reflects impairment of goodwill for Building & Construction.(4)   Reflects legal and other costs related to the ATRM merger and holding company conversion.(5)   Reflects write-off of costs related to a potential offering of preferred stock the Company did not complete.(6)   Reflects purchases related to COVID-19 Personal Protection Equipment.(7)   Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year, and sum of individual items may not equal the total.

Star Equity Holdings, Inc.Reconciliation of Non-GAAP Financial Measures(Unaudited)(In thousands)

For the Three Months Ended December 31, 2020 Diagnostic Services Diagnostic Imaging Building & Construction Real Estate & Investments Corporate, eliminations and other Total
             
Net income (loss) from continuing operations $991  $3,257  $(1,063) $(97) $(3,585) $(497)
Depreciation and amortization 305  71  450  86    912 
Interest expense (income) 19  (2) 202    65  284 
Income tax (benefit) expense (2) 11  34      43 
EBITDA from continuing operations 1,313  3,337  (377) (11) (3,520) 742 
             
Unrealized loss on equity securities (1)         11  11 
Litigation costs (2)         318  318 
Stock-based compensation         142  142 
Goodwill impairment (3)     436      436 
Financing costs     68    10  78 
Personal protection equipment (6)   17        17 
SBA PPP Loan forgiveness   (2,470)       (2,470)
Non-GAAP adjusted EBITDA from continuing operations $1,313  $884  $127  $(11) $(3,039) $(726)

For the Three Months Ended December 31, 2019 Diagnostic Services Diagnostic Imaging Building & Construction Real Estate & Investments Corporate, eliminations and other Total
             
Net income (loss) from continuing operations $1,726  $1,822  $(644) $24  $(3,219) $(291)
Depreciation and amortization 335  63  587  (52)   933 
Interest expense 24    173    116  313 
Income tax expense   (102)       (102)
EBITDA from continuing operations 2,085  1,783  116  (28) (3,103) 853 
Unrealized gain on equity securities (1)         (33) (33)
Stock-based compensation         124  124 
Transaction costs (4)         284  284 
Non-GAAP adjusted EBITDA from continuing operations $2,085  $1,783  $116  $(28) $(2,728) $1,228 

For the Twelve Months Ended December 31, 2020 Diagnostic Services Diagnostic Imaging Building & Construction Real Estate & Investments Corporate, eliminations and other Total
             
Net income (loss) from continuing operations $3,926  $5,586  $(2,811) $(363) $(11,623) $(5,285)
Depreciation and amortization 1,222  260  2,172  282    3,936 
Interest expense 75  7  910    300  1,292 
Income tax expense 10  79  40      129 
EBITDA from continuing operations 5,233  5,932  311  (81) (11,323) 72 
             
Unrealized gain on equity securities (1)         (22) (22)
Litigation costs (2)         562  562 
Stock-based compensation         525  525 
Goodwill impairment (3)     436      436 
Transaction cost (4)         115  115 
Financing cost     68    10  78 
Personal protection equipment (6)   63        63 
SBA PPP Loan forgiveness   (2,470)       (2,470)
Non-GAAP adjusted EBITDA from continuing operations $5,233  $3,525  $815  $(81) $(10,133) $(641)

For the Twelve Months Ended December 31, 2019 Diagnostic Services Diagnostic Imaging Building & Construction Real Estate & Investments Corporate, eliminations and other Total
             
Net income (loss) from continuing operations $6,667  $3,741  $(772) $(276) $(12,100) $(2,740)
Depreciation and amortization 1,277  278  711  165    2,431 
Interest expense 87    212    447  746 
Income tax (benefit) expense   (200) 1      (199)
EBITDA from continuing operations 8,031  3,819  152  (111) (11,653) 238 
             
Unrealized gain on equity securities (1)         (62) (62)
Loss on extinguishment of debt   151        151 
Stock-based compensation         540  540 
Write off of Star Real Estate Holding Assets       143    143 
Transaction cost (4)         2,342  2,342 
Write off of preferred stock issuance cost (5)         273  273 
Non-GAAP adjusted EBITDA from continuing operations $8,031  $3,970  $152  $32  $(8,560) $3,625 
                         

(1)   Reflects change in fair value of investments in equity securities.(2)   Reflects one-time litigation costs.(3)   Reflects impairment of goodwill for Building & Construction.(4)   Reflects legal and other costs related to the ATRM merger and holding company conversion.(5)   Reflects write-off of costs related to a potential offering of preferred stock the Company did not complete.(6)   Reflects purchases related to COVID -19 Personal Protection Equipment.

Star Equity Holdings, Inc. Reconciliation of Operating Cash Flow to Free Cash Flow(Unaudited)(In thousands)

  Three Months Ended December 31, Twelve Months Ended December 31,
  2020 2019 2020 2019
Net cash (used in) provided by operating activities $(3,073) $1,165  $(4,953) $400 
Less purchases of property and equipment (847) (330) (1,493) (1,512)
Gross Free Cash Flow (3,920) 835  (6,446) (1,112)
Plus net dispositions 5  238  161  1,734 
Plus merger related net working capital adjustment   284  115  2,342 
Plus SBA PPP Loan forgiveness 2,470    2,470   
Free cash flow $(1,445) $1,357  $(3,700) $2,964 
                 

Star Equity Holdings, Inc. Supplemental Debt Information(Unaudited)(In thousands)

A summary of the Company’s credit facilities and related party notes are as follows (in thousands):

  December 31, 2020 December 31, 2019
  Amount Weighted-Average Interest Rate Amount Weighted-Average Interest Rate
Revolving Credit Facility - Gerber KBS $1,099  6.00% $1,111  7.50%
Revolving Credit Facility - Premier   % 2,925  6.25%
Revolving Credit Facility - Gerber EBGL 2,016  6.00%   %
Total Short-Term Revolving Credit Facilities $3,115  6.00% $4,036  6.59%
Revolving Credit Facility - SNB $12,710  2.64% $17,038  4.26%
Total Long-Term Revolving Credit Facilities $12,710  2.64% $17,038  4.26%
LSV Co-Invest I Promissory Note (“January Note”) $709  12.00% $595  12.00%
LSV Co-Invest I Promissory Note (“June Note”) 1,220  12.00% 1,023  12.00%
LSVM Note 378  12.00% 302  12.00%
Total Notes Payable From Related Parties $2,307  12.00% $1,920  12.00%
Short Term Paycheck Protection Program Notes $1,857  1.00% $  %
Long Term Paycheck Protection Program Notes 2,321  1.00%   %
Total Paycheck Protection Program Notes $4,178  1.00% $  %
               

Term Loan Facilities

The following table presents the Star and Premier term loans balance net of unamortized debt issuance costs as of December 31, 2020 (in thousands):

  December 31, 2020
  Amount
Gerber - Star Term Loan $1,633 
Premier - Term Loan 740 
Total Principal 2,373 
Unamortized debt issuance costs (314)
Total $2,059 
     

Star Equity Holdings, Inc.Supplemental Segment Information(Unaudited)(In thousands)

  Three Months Ended December 31, Twelve Months Ended December 31,
  2020 2019 (1) 2020 2019 (1)
Revenue by segment:        
Diagnostic Services $10,602  $12,009  $39,267  $47,723 
Diagnostic Imaging 2,722  4,949  9,965  13,872 
Star Building & Construction 9,818  8,528  28,879  11,257 
Star Real Estate & Investments 160  232  685  275 
Corporate, eliminations and other (158) (158) (633) (193)
Consolidated revenue $23,144  $25,560  $78,163  $72,934 
         
Gross profit by segment:        
Diagnostic Services $1,723  $2,690  $6,758  $10,237 
Diagnostic Imaging 891  2,096  3,391  5,136 
Star Building & Construction 1,340  1,536  4,047  2,013 
Star Real Estate & Investments 95  167  424  (33)
Corporate, eliminations and other (158) (158) (633) (193)
Consolidated gross profit $3,891  $6,331  $13,987  $17,160 
         
Income (loss) from continuing operations by segment:        
Diagnostic Services $984  $1,874  $3,888  $6,788 
Diagnostic Imaging 544  1,621  2,136  3,283 
Star Building & Construction (464) 397  (2,909) 307 
Star Real Estate & Investments 61  (52) 270  (312)
Corporate, eliminations and other (158) (158) (633) (193)
Unallocated corporate and other expenses (3,078) (3,545) (9,524) (9,440)
Segment (loss) income from operations (2,111) 137  (6,772) 433 
Goodwill impairment (2) (436)   (436)  
Merger and finance costs (3)   (284)   (2,342)
Consolidated loss from operations $(2,547) $(147) $(7,208) $(1,909)
         
Depreciation and amortization by segment:        
Diagnostic Services $305  $335  $1,222  $1,277 
Diagnostic Imaging 71  63  260  278 
Star Building & Construction 450  587  2,172  711 
Star Real Estate & Investments 86  (52) 282  165 
Total depreciation and amortization $912  $933  $3,936  $2,431 
                 

(1) Segment information has been recast for all periods presented to reflect the allocation of corporate and other expenses.(2) Reflects impairment of goodwill related to EBGL reporting unit.(3) Reflects legal and other costs related to the ATRM merger and holding company establishment.

Primary Logo

Source: Star Equity Holdings, Inc.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Globe Newswire, Press Releases

Related Entities

Dividend, Earnings, Definitive Agreement